Evidence map›Paper›PMID 32576063›Full record

ArticleSLAS technology2020

An Intestine-on-a-Chip Model of Plug-and-Play Modularity to Study Inflammatory Processes.

Linda Gijzen, Diego Marescotti, Elisa Raineri, Arnaud Nicolas, Henriette L Lanz, Diego Guerrera, Remko van Vught, Jos Joore, Paul Vulto, Manuel C Peitsch and 3 more

Abstract read
In one paragraph

Article in SLAS technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Cytokine-Induced Barrier Dysfunction and Lipid Signaling in a Gut-On-Chip Model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  8. Article
  9. Emerging advances in intestinal models for in vitro preclinical research.American journal of physiology. Gastrointestinal and liver physiology · 2025
    Review
  10. Gastrointestinal tract, its pathophysiology andWorld journal of gastroenterology · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. "ArmedFrontiers in cell and developmental biology · 2025
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linda GijzenMimetas BV, Leiden, The Netherlands.
Diego MarescottiPMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.ORCID 0000-0003-1007-8074
Elisa RaineriMimetas BV, Leiden, The Netherlands.
Arnaud NicolasMimetas BV, Leiden, The Netherlands.
Henriette L LanzMimetas BV, Leiden, The Netherlands.
Diego GuerreraPMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Remko van VughtMimetas BV, Leiden, The Netherlands.
Jos JooreMimetas BV, Leiden, The Netherlands.
Paul VultoMimetas BV, Leiden, The Netherlands.
Manuel C PeitschPMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Julia HoengPMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Giuseppe Lo SassoPMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Dorota KurekMimetas BV, Leiden, The Netherlands.ORCID 0000-0002-7168-8944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of efficient drugs and therapies for the treatment of inflammatory conditions in the intestine is often hampered by the lack of reliable, robust, and high-throughput in vitro and in vivo models. Current models generally fail to recapitulate key aspects of the intestine, resulting in low translatability to the human situation. Here, an immunocompetent 3D perfused intestine-on-a-chip platform was developed and characterized for studying intestinal inflammation. Forty independent polarized 3D perfused epithelial tubular structures were grown from cells of mixed epithelial origin, including enterocytes (Caco-2) and goblet cells (HT29-MTX-E12). Immune cells THP-1 and MUTZ-3, which can be activated, were added to the system and assessed for cytokine release. Intestinal inflammation was mimicked through exposure to tumor necrosis factor-α (TNFα) and interleukin (IL)-1β. The effects were quantified by measuring transepithelial electrical resistance (TEER) and proinflammatory cytokine secretion on the apical and basal sides. Cytokines induced an inflammatory state in the culture, as demonstrated by the impaired barrier function and increased IL-8 secretion. Exposure to the known anti-inflammatory drug TPCA-1 prevented the inflammatory state. The model provides biological modularity for key aspects of intestinal inflammation, making use of well-established cell lines. This allows robust assays that can be tailored in complexity to serve all preclinical stages in the drug discovery and development process.

Indexed as

Intestinal MucosaLab-On-A-Chip DevicesCaco-2 CellsHumansIntestinesbarrier integrityhigh-throughputintestinal inflammationmicrofluidicsplug-and-play complexity

Identifiers

PMID32576063
PMCPMC7684793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.